Home Journals Articles Updates About
CN
image
收藏切换
Traditional Chinese medicine for chronic obstructive pulmonary disease: treatment strategies, clinical evidence, and mechanistic insights
收藏切换
PDF
Jiansheng Li1, 2, *, Yang Xie1, 2, Peng Zhao2, Siyuan Lei1, 2
Acupuncture and Herbal Medicine | 2026, 6(3) : 314 - 325
Less
收藏切换
Acupuncture and Herbal Medicine | 2026, 6(3): 314-325
• Review Articles •
Traditional Chinese medicine for chronic obstructive pulmonary disease: treatment strategies, clinical evidence, and mechanistic insights
Full
Jiansheng Li1, 2, *, Yang Xie1, 2, Peng Zhao2, Siyuan Lei1, 2
Affiliations
  • 1Lung Disease Diagnosis and Treatment Center, National Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
  • 2Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province & Education Ministry of P.R. China/Henan Key Laboratory of Chinese Medicine for Respiratory Diseases, Henan University of Chinese Medicine, Zhengzhou, China
Published: 2026-09-25 doi: 10.1097/HM9.0000000000000208
Outline
收藏切换

Chronic obstructive pulmonary disease (COPD) is a prevalent, preventable, and treatable chronic airway disease associated with high morbidity, mortality, and global burden. In this review, we searched PubMed, Web of Science, and major Chinese academic databases for clinical and mechanistic studies of traditional Chinese medicine (TCM) interventions for COPD, emphasizing evidence relevant to the stable phase, acute exacerbation phase, and first 8 weeks after an exacerbation, termed the acute exacerbation of COPD (AECOPD) risk window phase (risk window). Evidence from randomized trials and evidence syntheses indicates that adjunctive herbal formulae, Chinese patent medicines, acupuncture, moxibustion, acupoint-based interventions, and traditional Chinese exercise therapy may improve symptoms, the 6-minute walking distance (6MWD), pulmonary function indices, quality of life, and selected exacerbation-related outcomes. Multicenter trials have also reported benefits of syndrome-based sequential treatment during acute exacerbation and the subsequent risk window. Mechanistic studies suggest coordinated regulation of inflammatory and oxidative stress pathways, immune homeostasis, epithelial barrier integrity, mucus hypersecretion, apoptosis, and airway remodeling. However, confidence in these findings is limited by heterogeneous syndrome definitions and intervention protocols, small samples, incomplete blinding and allocation reporting, and insufficient long-term follow-up. Future research should prioritize standardized diagnostic criteria and outcomes, rigorously designed multicenter trials, and translational studies that link in vivo active substances and molecular targets to clinically meaningful outcomes.

Acupuncture  /  Chinese exercise therapy  /  Chinese herbal medicine  /  Chronic obstructive pulmonary disease  /  Traditional Chinese medicine
Jiansheng Li, Yang Xie, Peng Zhao, Siyuan Lei. Traditional Chinese medicine for chronic obstructive pulmonary disease: treatment strategies, clinical evidence, and mechanistic insights[J]. Acupuncture and Herbal Medicine, 2026 , 6 (3) : 314 -325 . DOI: 10.1097/HM9.0000000000000208
Full Text
Less
Funding
Less
  • National Key R&D Program of China(2023YFC3502600)
  • National Natural Science Foundation of China Key Project(81830116)
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project(2023ZD0506700; 2023ZD0506704)
References
Less
[1]
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org. Accessed June 5, 2026.
[2]
GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 2025;406(10513):1811–1872.
[3]
Chen S, Kuhn M, Prettner K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. Lancet Glob Health 2023;11(8):e1183–e1193.
[4]
van Geffen WH, Tan DJ, Walters JA, et al. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and longacting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2023;12(12):CD011600.
[5]
Moll M, Silverman EK. Precision approaches to chronic obstructive pulmonary disease management. Annu Rev Med 2024;75:247–262.
[6]
Al Wachami N, Guennouni M, Iderdar Y, et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMC Public Health 2024;24(1):297.
[7]
Fan Y, Chen Q, Sun H, et al. Economic evaluations of screening and case-finding for chronic obstructive pulmonary disease (COPD): a systematic review. NPJ Prim Care Respir Med 2026;36(1):7.
[8]
Li J, Xie Y, Wang M, et al. Effect of traditional Chinese medicine combined with conventional Western medicine for patients with severe/very severe chronic obstructive pulmonary disease: a multi-center, randomized, double-blind, controlled study. Chin Med 2025;20(1):66.
[9]
Li J, Zhang H, Wang J, et al. Efficacy and safety of Supine Daoyin in the treatment of acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. J Evid Based Med 2024;17(3):654–666.
[10]
Yu X, Di J, Zhang W, et al. Bu-Fei Yi-Shen granules reduce acute exacerbations in patients with GOLD 3-4 COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis 2023;18:2439–2456.
[11]
Li JS, Yu XQ. Strategy of traditional Chinese medicine prevention and treatment of chronic obstructive pulmonary disease based on classification of stages and grades. J Tradit Chin Med 2019;60(22):1895–1899.
[12]
Li JS. Accumulation of pathogen and damage due to deficiency of vital qi is the main pathogenesis of chronic obstructive pulmonary diseases. China J Tradit Chin Med Pharm 2011;26(8):710–713.
[13]
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128–1138.
[14]
Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179(5):369–374.
[15]
Li JS, Wang HF. Sequential syndrome differentiation by eliminating pathogen and strengthening vital qi on the basis of acute exacerbation of chronic obstructive pulmonary disease risk window. Chin J Integr Med 2011;31(9):1276–1280.
[16]
Ding J, Tao H, Cheng G, et al. HAN Mingxiang's experience in staged and syndrome-based treatment of chronic obstructive pulmonary disease. J Tradit Chin Med 2025;66(8):780–785.
[17]
Wu M, Li H. Clinical observation of Yiqi Wenyang Huatan Decoction combined with auricular point seed-pressing therapy for the treatment of patients in the risk-window of acute exacerbation of chronic obstructive pulmonary disease. J Guangzhou Univ Tradit Chin Med 2023;40(4):838–845.
[18]
Respiratory Disease Committee of the Chinese Association of Integrative Medicine, Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province and the Ministry of Education, The First Affiliated Hospital of Henan University of Chinese Medicine/National Medical Center for Chinese Medicine. Traditional Chinese medicine syndrome diagnostic criteria for the risk window of acute exacerbation of chronic obstructive pulmonary disease (2025). J Tradit Chin Med 2025;66(18):1958–1961. doi:10.13288/j.11-2166/r.2025.18.017.
[19]
China Association of Chinese Medicine. Diagnosis and treatment guideline for Chinese medicine on chronic obstructive pulmonary disease. T/CACM 1319-2019[S]. Beijing: China Association of Chinese Medicine; 2019.
[20]
Internal Medicine Committee of World Federation of Chinese Medicine Societies. Guideline of integrated Chinese and Western medicine for diagnosis and treatment of chronic obstructive pulmonary disease. Chin J Evid Based Med 2023;23(10):1117–1128.
[21]
Professional Committee of Pulmonary Diseases, Internal Medicine Branch, China Association of Chinese Medicine. Diagnostic criteria for traditional Chinese medicine syndromes of chronic obstructive pulmonary disease (2011 edition). J Tradit Chin Med 2012;53(2):177–178.
[22]
Lyu T, Li D, Lei X, et al. Effects of the Chinese herbal formula San-Huang Gu-Ben Zhi-Ke treatment on stable chronic obstructive pulmonary disease: a randomized, double-blind, placebo- controlled trial. Front Pharmacol 2023;14:1164818.
[23]
Li J, Yuan Q, Yu R, et al. Evidence map analysis of clinical studies on 42 commonly used oral Chinese patent medicines for the treatment of stable chronic obstructive pulmonary disease. J Ethnopharmacol 2026;355(Pt B):120707.
[24]
Li Y, Lei SY, Ma YZ, et al. Network meta-analysis of Chinese patent medicines for the treatment of stable chronic obstructive pulmonary disease. World Chin Med 2024;19(10):1435–1446.
[25]
Li J, Wang M, Xie Y, et al. A randomized, double-blinded, placebo- controlled study of the use of traditional Chinese medicine for treating patients with mild/moderate chronic obstructive pulmonary disease. J Evid Based Med 2025;18(2):e70023.
[26]
Guo SJ, Sun ZT, Li YC, et al. Effect of bufei granules on the serum IL-33/sST2 axis and related inflammatory cytokines in mild-to-moderate chronic obstructive pulmonary disease stable phase patients: a multi-center, double-blinded, randomized controlled trial. CJITWM 2018;38(9):1034–1039.
[27]
Chen Y, Gong X, Zhou M, et al. Treatment with JianPiYiFei II granules for patients with moderate to very severe chronic obstructive pulmonary disease: a 52-week randomised, doubleblinded, placebo-controlled, multicentre trial. Phytomedicine 2022;100:154057.
[28]
Peng JQ, Ye WX, Fan FC. Effects of Jinshui Liujun decoction on clinical symptoms and inflammatory response in patients with severe and very severe chronic obstructive pulmonary disease. Chin J Gerontol 2020;40(13):2759–2762.
[29]
Hua R, Zhang JC, Hu JX. Effects of modified Qiwei Duqi Pills assisting budesonide formoterol powder inhaler combined with tiotropium bromide on pulmonary function, serum creatinine, immune factors and T lymphocyte subsets expression levels in patients with severe COPD. Chin Arch Tradit Chin Med 2024;42(8):199–203.
[30]
Zhang YY, Zhang MZ, Ma QQ, et al. Network meta- analysis of Chinese patent medicines in treatment of stable chronic obstructive pulmonary disease. China J Chin Mater Med 2025;50(1):248–266.
[31]
Li H, Xu XF, Zhou QL, et al. Efficacy of astragalus on chronic obstructive pulmonary disease: a meta-analysis. Chin Gen Pract 2013;16(9):805–807.
[32]
Wen G, Xuanlin L, Hulei Z, et al. Effectiveness of Chinese herbal medicine combined with conventional medicine on acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Tradit Chin Med 2023;43(2):212–220.
[33]
Li J, Zhang H, Ruan H, et al. Effects of Chinese herbal medicine on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis 2020;15:2901–2912.
[34]
Respiratory Drug Research Committee of China Association of Chinese Medicine, Standardization Project Team for the Clinical Application Guidelines for Integrated Traditional Chinese and Western Medicine in the Prevention and Treatment of Chronic Obstructive Pulmonary Disease. Clinical application guidelines for integrated traditional Chinese and Western medicine in the prevention and treatment of chronic obstructive pulmonary disease. CJITWM 2025;45(11):1285–1304.
[35]
Wang HM, Li HT, Zhang J, et al. The efficacy of modified minor green dragon decoction on chronic obstructive pulmonary disease in acute attack period and its influence on inflammatory factors. Henan Tradit Chin Med 2023;43(3):340–344.
[36]
Luo GP, Mo CY, Yuan GZ, et al. Effect of modified Sanzi Yangqin decoction on IL-32 expression in patients with acute exacerbation of chronic obstructive pulmonary disease. China Modern Doctor 2019;57(9):13–15,20.
[37]
Liu R, Hou TB, He J, et al. Clinical efficacy of modified Qingqi Huatan Wan in treatment of acute exacerbation of chronic obstructive pulmonary disease with syndrome of phlegm-heat obstructing lung and effect on serum TNF-α, IL-8 and MMP-9. Chin J Exper Tradit Med Formulae 2019;25(9):31–37.
[38]
Du X, Chen Y, Zhang R, et al. Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Front Pharmacol 2024;15:1466677.
[39]
Yu XY, Yan HQ, Su YH, et al. Clinical efficacy of Qingke Pingchuan Granules in treatment of AECOPD (phlegm heat stagnation lung syndrome) and its impact on serum IL-6 and PCT. Chin Tradit Herbal Drugs 2024;55(11):3768–3773.
[40]
Zhang ZJ, Cui HS, Huang GR, et al. Clinical observation on treatment of acute exacerbation of chronic obstructive pulmonary disease (syndrome of phlegm-heat obstructing lung) with Qingke Pingchuan Granules. Chin J Exper Tradit Med Formulae 2024;30(16):85–91.
[41]
Peng GY, Liu X, Zhang D, et al. Clinical observation of Shiwei Longdanhua capsule combined with salmeterolotecasone in treatment of AECOPD patients and its effect on airway remodeling. Chin Arch Tradit Chin Med 2019;37(10):2487–2491.
[42]
Huang R, Xiao J. Clinical effect of feilike mixture combined with Western medicine on acute exacerbation of chronic obstructive pulmonary disease. Drug Eval 2023;20(2):183–186.
[43]
Feng Y, Huo HJ, Tang Q. Clinical study of Qingfei Xiaoyan Pills combined with salbutamol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Drugs Clinic 2021;36(12):2546–2551.
[44]
Hu H, Ji Z, Qiang X, et al. Chinese medical injections for acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2021;16:3363–3386.
[45]
Li J, Wang H, Li S, et al. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window. Complement Ther Med 2016;29:109–115.
[46]
Li J, Zhang H, Ruan H, et al. Efficacy and safety of Chinese medicine in treating risk window of AECOPD: a multicenter randomized controlled trial. Phytomedicine 2025;144:156903.
[47]
Shang WX. Clinical study of Ningfeidingchuan Formula in treatmenting patients with dangerous window of acute exacerbation stage of chronic obstructive pulmonary disease. Guangzhou: Guangzhou University of Chinese Medicine, 2018.
[48]
Wang YW, Chen N, Zhao HF, et al. Clinical observation of Xuanfei Huatan Tongluo method on AECOPD risk window. JETCM 2021;30(3):443–446.
[49]
Li J, Xie Y, Wang Y, et al. Effect of acupuncture on patients with chronic obstructive pulmonary disease: a multicenter randomized controlled trial. Complement Ther Med 2025;89:103146.
[50]
Lin X, Wang M, Yang J, et al. Literature evaluation and meta-analysis of clinical effect of lung benefiting moxibustion on chronic obstructive pulmonary disease. Chin J Gerontol 2023;43(12):2865–2871.
[51]
Xiao Q, Meng Y, Wang G, et al. Effects of Wenfei Guyuan umbilical moxibustion on patients with stable chronic obstructive pulmonary disease: a multicenter randomized controlled trial. Complement Ther Med 2025;92:103194.
[52]
Chen H, Chen L, Xu J, et al. Effect of governor vessel moxibustion on cardiopulmonary fitness in stable chronic obstructive pulmonary disease with qi deficiency of lung and kidney. Chin Acupunct Moxibustion 2025;45(12):1717–1722.
[53]
Polkey MI, Qiu ZH, Zhou L, et al. Tai Chi and pulmonary rehabilitation compared for treatment-naive patients with COPD: a randomized controlled trial. Chest 2018;153(5):1116–1124.
[54]
Chen X, Fu C, Wang X, et al. Combined effect of 12 weeks Baduanjin and tri-ball respiratory training as a home-based pulmonary rehabilitation in subjects with moderate chronic obstructive pulmonary disease: a multi-center randomized controlled trial. Rehabil Nurs 2025;50(2):78–87.
[55]
Zhu Z, Muhamad AS, Omar N, et al. Effects of Mawangdui exercise intervention on the pulmonary function, physical fitness and quality of life in stable chronic obstructive pulmonary disease patients: a randomised controlled trial. Complement Ther Med 2025;89:103152.
[56]
Zhang HL, Li JS, Yu XQ, et al. An evaluation of activity tolerance, patient-reported outcomes and satisfaction with the effectiveness of pulmonary daoyin on patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017;12:2333–2342.
[57]
Liu P, Li Y, Tang D, et al. Effects of different traditional Chinese exercises on pulmonary function in patients with stable chronic obstructive pulmonary disease: a network meta-analysis. BMC Complement Med Ther 2024;24(1):304.
[58]
Xin Y, Yuan S, Tong J, et al. Application effect of method of invigorating Qi and dredging collateral, invigorating spleen and tonifying kidney combined with acupoint application in patients with chronic obstructive pulmonary disease at stable stage. Liaoning J Tradit Chin Med 2024;51(8):82–86.
[59]
Ergin C, Karadağ S. Effects of acupressure on dyspnea and anxiety in patients with chronic obstructive pulmonary disease: a randomized controlled trial. Explore (NY) 2026;22(2):103326.
[60]
Li M, Zheng S, Lederer AK, et al. Efficacy of acupuncture-based treatment in chronic obstructive pulmonary disease—a systematic review and meta-analysis. Complement Ther Med 2025;93:103211.
[61]
Liao S, Wang F, Lin Q, et al. Effect of sitting and lying Liuzijue exercise for pulmonary rehabilitation in acute exacerbation of chronic obstructive pulmonary disease patients with non-invasive ventilation: a randomized controlled trial. Ann Palliat Med 2021;10(9):9914–9926.
[62]
Zhou LM, Zhang XM, Dai Y. Application of sitting Baduanjin combined with patting the hand Taiyin lung meridian in patients with acute exacerbation of chronic obstructive pulmonary disease. J Clin Nurs 2021;20(6):18–20.
[63]
Wang JJ. The Effects of Tunahuichun Gong on the Early Pulmonary Rehabilitation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Chengdu University of Traditional Chinese Medicine, 2020.
[64]
Wang JJ, Han L, Zhou PC. Effectiveness evaluation of exhalationinhalation exercise on early pulmonary rehabilitation for patients with acute exacerbation of chronic obstructive pulmonary disease. J Tradit Chin Med 2026;67(4):432–438.
[65]
Geng Y, Wang L, Geng L, et al. Effects of Thunder-Fire moxibustion combined with respiratory rehabilitation training on cardiopulmonary function and exercise endurance in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. Chin J Gerontol 2023;43(12):2872–2876.
[66]
Shen A, Zhang F, Hu J, et al. Effect of clearing lung and eliminating phlegm and removing blood stasis method combined with acupoint application on phlegm–heat stagnation syndrome in patients with acute exacerbation of chronic obstructive pulmonary disease. Liaoning J Tradit Chin Med 2025;52(6):91–95.
[67]
Peng L, Xia W, He J, et al. Effect of early TCM pulmonary rehabilitation with “AECOPD risk window” as the intervention point on AECOPD patients. J Emerg Tradit Chin Med 2020;29(9):1583–1586 + 1605.
[68]
Liu M. The Effect of Breathing Turtle Work on Patients With AECOPD With “AECOPD Risk Window” as Intervention Point. Chengdu University of Traditional Chinese Medicine, 2023.
[69]
Sun X. Observation on the Clinical Effect of Baduanjin Rehabilitation Therapy on Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease During the Risk Window Phase. Nanjing University of Chinese Medicine, 2024.
[70]
Suzuki M, Takahashi Y, Inoue D, et al. Effectiveness of a long-term acupuncture treatment in patients with COPD: a randomised controlled trial. ERJ Open Res 2025;11(3):00668–02024.
[71]
Yang P, Xu W, Fu T. Press needle exercise therapy for stable chronic obstructive pulmonary disease: a randomized controlled trial. Chin Acupunct Moxibustion 2025;45(8):1042–1046.
[72]
Xiao Q, Meng Y, Wang G, et al. Influence of Wenfei Guyuan umbilical moxibustion on quality of life and immune function in patients with chronic obstructive pulmonary disease in stable phase. Chin J Exper Tradit Med Formulae 2026;32(7):241–250.
[73]
Wang J, Hu D, Pan J, et al. Clinical observation on warming needle combined with low-intensity resistance exercise training in the treatment of chronic obstructive pulmonary disease. Shanghai J Acu-mox 2025;44(8):930–935.
[74]
Coyle ME, Liu S, Zhang AL, et al. Acupuncture point injection therapy plus pharmacotherapy for chronic obstructive pulmonary disease: a systematic review of randomised controlled trials. Eur J Integr Med 2015;7(6):567–576.
[75]
Wang K, Shen F, Cheng YX. Effects of herbal atomization combined with acupuncture on inflammatory responses and sputum microbiota in patients with AECOPD with phlegm-heat constraint in the lung. Chin J Microecol 2024;36(9):1048–1053,1065.
[76]
Lu Q, Chen Z, Mu BX, et al. Mechanism study and clinical observation of Jia Wei Su Zi Jiang qi formula in reducing mucus hypersecretion in patients with chronic obstructive pulmonary disease. J Ethnopharmacol 2025;353(Pt A):120363.
[77]
Shen DD, Yang ZH, Huang J, et al. Liuweibuqi capsules improve pulmonary function in stable chronic obstructive pulmonary disease with lung-qi deficiency syndrome by regulating STAT4/STAT6 and MMP-9/TIMP-1. Pharm Biol 2019;57(1):744–752.
[78]
Albano GD, Gagliardo RP, Montalbano AM, et al. Overview of the mechanisms of oxidative stress: impact in inflammation of the airway diseases. Antioxidants (Basel) 2022;11:2237.
[79]
Gao W, Guo L, Yang Y, et al. Dissecting the crosstalk between Nrf2 and NF-κB response pathways in drug-induced toxicity. Front Cell Dev Biol 2022;9:809952.
[80]
Wang K, Tao L, Zhang Q, et al. Bufei Jianspi formula alleviates intestinal epithelial barrier injury by inhibition of calpain 2 in COPD rat. Phytomedicine 2026;154:158006.
[81]
Mao J, Li Y, Feng S, et al. Bufei Jianpi formula improves mitochondrial function and suppresses mitophagy in skeletal muscle via the adenosine monophosphate-activated protein kinase pathway in chronic obstructive pulmonary disease. Front Pharmacol 2020;11:587176.
[82]
Zhao P, Li J, Tian Y, et al. Restoring Th17/Treg balance via modulation of STAT3 and STAT5 activation contributes to the amelioration of chronic obstructive pulmonary disease by Bufei Yishen formula. J Ethnopharmacol 2018;217:152–162.
[83]
Zhao M, Huang Z, Zheng J, et al. MiR-340-5p alleviates AECOPD by targeting MAP3K2 via Qingjin Huatan decoction therapy. J Leukoc Biol 2025;117(4):021.
[84]
Liu P, Yang H, Long F, et al. Bioactive equivalence of combinatorial components identified in screening of an herbal medicine. Pharm Res 2014;31(7):1788–1800.
[85]
Yang H, Qi LW, Li HJ, et al. Constructing a quality control system for traditional Chinese medicine using ”active ingredients cluster“ as the labeled quantity. World Sci Technol Mod Tradit Chin Med Mater Med 2014;16(3):510–513.
[86]
Zhang H, Luo LP, Song HP, et al. A high-resolution peak fractionation approach for streamlined screening of nuclear- factor-E2-related factor-2 activators in Salvia miltiorrhiza. J Chromatogr A 2014;1326:47–55.
[87]
Wang XJ. Methodology for systematic analysis of in vivo efficacy material base of traditional Chinese medicine—Chinmedomics. Zhongguo Zhong Yao Za Zhi 2015;40(1):13–17.
[88]
Liu SB, Sun H, Lu SW, et al. Deciphering the Q-markers of nourishing kidney-yin of Cortex Phellodendri amurense from ZhibaiDihuang pill based on Chinmedomics strategy. Zhong Yi Yao Xue Bao 2021;10:14–22.
[89]
Mei XF, Zhao P, Lu RL, et al. Comparative study on establishment of a mouse model of chronic obstructive pulmonary disease. Chin J Pathophysiol 2022;38(1):178–185.
[90]
Liu X, Zhao P, Wang L, et al. Screening effective-component compatibility from Jinshui Chenfei formula for silicosis treatment by serum-pharmacochemistry and feedback system control. Phytomedicine 2025;138:156419.
[91]
Li J, Zhao P, Yang L, et al. System biology analysis of longterm effect and mechanism of Bufei Yishen on COPD revealed by system pharmacology and 3-omics profiling. Sci Rep 2016;6:25492.
[92]
Li J, Zhao P, Li Y, et al. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease. Sci Rep 2015;5:15290.
[93]
Wu J, Cai B, Zhang A, et al. Chemical identification and antioxidant screening of Bufei Yishen formula using an offline DPPH ultrahigh-performance liquid chromatography Q-Extractive Orbitrap MS/MS. Int J Anal Chem 2022;2022:1423801.
[94]
Li JS, Liu XF, Dong HR, et al. Effective-constituent compatibility-based analysis of Bufei Yishen formula, a traditional herbal compound as an effective treatment for chronic obstructive pulmonary disease. J Integr Med 2020;18(4):351–362.
[95]
Li J, Ma J, Tian Y, et al. Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling. J Ethnopharmacol 2020;257:112796.
[96]
Li J, Zhao P, Tian Y, et al. The anti-inflammatory effect of a combination of five compounds from five Chinese herbal medicines used in the treatment of COPD. Front Pharmacol 2021;12:709702.
[97]
Wei Y, Liu X, Jiang Y, et al. Maintenance of airway epithelial barrier integrity via the inhibition of AHR/EGFR activation ameliorates chronic obstructive pulmonary disease using effectivecomponent combination. Phytomedicine 2023;118:154980.
[98]
Li MY, Qin YQ, Tian YG, et al. Effective-component compatibility of Bufei Yishen formula III ameliorated COPD by improving airway epithelial cell senescence by promoting mitophagy via the NRF2/PINK1 pathway. BMC Pulm Med 2022;22(1):434.
[99]
Li H, Wang P, Li W, et al. Key issues and essential points in non-clinical pharmacology of traditional Chinese medicine formulas: enhancing the scientization and standardization. Acupunct Herb Med 2025;5(4):379–399.
[100]
Wang C, Ding H, Tang X, et al. Effect of Liuweibuqi capsules in pulmonary alveolar epithelial cells and COPD through JAK/STAT pathway. Cell Physiol Biochem 2017;43(2):743–756.
Appendix
Less
Year 2026 volume 6 Issue 3
PDF
5
0
Cite this Article
BibTeX
Article Info
doi: 10.1097/HM9.0000000000000208
  • Receive Date：2026-06-09
  • Online Date：2026-11-04
  • Published：2026-09-25
Article Data
Affiliations
History
  • Received：2026-06-09
  • Accepted：2026-08-08
Funding
National Key R&D Program of China(2023YFC3502600)
National Natural Science Foundation of China Key Project(81830116)
Noncommunicable Chronic Diseases-National Science and Technology Major Project(2023ZD0506700; 2023ZD0506704)
Affiliations
    1Lung Disease Diagnosis and Treatment Center, National Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
    2Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province & Education Ministry of P.R. China/Henan Key Laboratory of Chinese Medicine for Respiratory Diseases, Henan University of Chinese Medicine, Zhengzhou, China

Corresponding:

* Jiansheng Li, E-mail: .
References
Share
https://castjournals.cast.org.cn/joweb/ahm/EN/10.1097/HM9.0000000000000208
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House